On August 26, 2019, the newly revised Drug Administration Law (“New Law”) was officially issued. The promulgation of the New Law has established a new legal regulatory framework, resulted in significant changes for the pharmaceutical and healthcare industry, and promoted international integration. Given its implications for current and future market participants, timely interpretation of the law is required by local and foreign companies operating in the Chinese healthcare sector. Continue Reading KWM releases Special Issue for the New Drug Administration Law(Chinese)